Clinical Trial Search

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Number of Patients With Treatment Related GI and/or GU Toxicity as Assessed by the NCI CTCTAE Version 4.0 — 1 Participants

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Time to Progression — 11.2 weeks

Primary: Acute and Late Genitourinary and Lower Gastrointestinal Toxicity Using the Radiation Therapy Oncology Group Acute and Late Morbidity Scales. — 11; 0; 0; 0 participants

Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Change in the Number of Infiltrating CD3+ T Cells Within the Prostate Tissue Between the Biopsy and the Post-RP Tissue Specimens in Each Subject — 2.33; 2.03; 1.98; 6.39…

Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months

Primary: Percentage of Participants With PSA50 Response — 2 Participants

Primary: Number of Subjects With Change From Baseline in the Mucinous Glycoprotein 1 (MUC1) Specific Systemic T-Cells Immune Response at Day 60 (Pre-Radiation) — 2; 3 Participants

Primary: Biochemical Control Rate — 71; 0 Participants

Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants

Primary: Progression at 6 Months — 11; 7 Participants

Primary: Percentage of Patients to Successfully Generate and Administer the Alpha-DC1 Vaccine — 100; 100 percentage of participants

Primary: Progression-free Survival (PFS) — 14.5; 10.7 months

Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…

Primary: Median Progression-Free Survival (PFS) — 6.0 months — p=0.001

Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g

Primary: Number of Participants Who Completed the Maximum Time Allowed on Study Without Severe Acute Surgical Complications — 11 Participants

Primary: Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation) — 6; 0 Participants

Primary: Change Rate of Prostate-specific Antigen (PSA) < Nadir + 2 ng/mL From First Day of Treatment to 15 Months (Cohort 2) — 100; 100 percentage of participants

Primary: Number of Participants With Deterioration in HVLT-R Delayed Recall Score at Six Months (Phase III) — 33; 27 Participants — p=0.28

Primary: Objective Response Rate — 3 Participants

Primary: Progression Free Survival. — 6.0 Months

Primary: Effect of Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) on Possible Delayed Recall Toxicity as Assessed by the Hopkins Verbal Learning Test-Revised (HVLT-R)…

Primary: Number of Participants Who Received At Least 1 Infusion of Sipuleucel-T in Men With Metastatic Castrate-resistant Prostate Cancer (CRPC) — 98 participants

Primary: Overall Survival (12-month Rate Reported) — 60.1; 50.8 percentage of participants — p=0.2103

Primary: Biochemical Disease-Free Survival (bDFS), Using Phoenix and ASTRO Definitions — 46; 27; 45; 27 Participants

Primary: 8-Week Progression-Free Rate — 0.0; 8.3 percentage of participants